
Apparent Discrepancy Between Published Study of Gabapentin Treatment and Internal Company Report

To the Editor: I was concerned to read the recent report by Vedula et al¹ that includes additional information obtained through litigation about an article published in the *Journal* (Vieta et al 2006²).

Specifically, the company report indicates that 42 participants were randomized, but Vieta et al report that “twenty-five subjects aged from 18 to 75 years with a diagnosis of bipolar I or II disorder (according to *DSM-IV* criteria) treated with any standard mood stabilizer like lithium, valproate, carbamazepine, or any combination during the last year were recruited.”^{2(p474)}

As there appears to be a discrepancy between the data submitted to the *Journal* and the company report, the latter should be made publicly available to allow readers to assess this study for themselves.

Thank you for your consideration.

REFERENCES

1. Vedula SS, Li T, Dickersin K. Differences in reporting of analyses in internal company documents versus published trial reports: comparisons in industry-sponsored trials in off-label uses of gabapentin. *PLoS Med*.

Letters to the Editor

2013;10(1):e1001378.

2. Vieta E, Manuel Goikolea J, Martínez-Arán A, et al. A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. *J Clin Psychiatry*. 2006;67(3):473–477.

Evan Mayo-Wilson, MPA, DPhil
e.mayo-wilson@ucl.ac.uk

Author affiliation: Centre for Outcomes Research and Effectiveness Research Clinical, Educational & Health Psychology University College London, London, United Kingdom.

Potential conflicts of interest: None reported.

Funding/support: None reported.

J Clin Psychiatry 2013;74(8):853–854 (doi:10.4088/JCP.13lr08420).

© Copyright 2013 Physicians Postgraduate Press, Inc.